The virus, known as HPgV-2, was detected in blood samples from individuals with concurrent hepatitis C virus infections.
The amendment changes product fees Abbott pays to BG Medicine for galectin-3 test sales in exchange for making two payments totaling $1 million.
The diagnostics manufacturer attributed the decline to the negative impact of foreign currency exchange and lower international sales.
Abbott's third quarter diagnostic revenues shrunk 2 percent and molecular diagnostics sales dropped 5 percent, both due to unfavorable currency effects.
With recent and impending launches of POC MDx platforms, some industry observers believe the technology could replace some POC immunoassays in a few years.
A number of firms now have FDA-approved Group A Strep assays, but end users may be hesitant to adopt them until Infectious Disease Society of America guidelines are updated.
The test runs on the firm's m2000 PCR platform and is the first on the market to assess resistance to both rifampin and isoniazid.
Total revenues in the quarter were $629.2 million, beating the Wall Street estimate of $625.2 million.
Second quarter diagnostic revenues decreased 1 percent year over year to $1.18 billion as molecular diagnostics sales shrunk a fraction of a percent.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.